{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:08:22Z","timestamp":1785186502738,"version":"3.55.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.4158\/ep.14.6.672","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T22:08:50Z","timestamp":1365199730000},"page":"672-677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Prevalence of Valvular Heart Disease in A Cohort of Patients Taking Cabergoline for Management of Hyperprolactinemia"],"prefix":"10.1016","volume":"14","author":[{"given":"Jessica K.","family":"Devin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul T.","family":"Lakhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Benjamin F.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Lewis S.","family":"Blevins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP.14.6.672_bb0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.14.6.672_bb0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade","year":"2007","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.14.6.672_bb0015","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1212\/01.wnl.0000238508.68593.1d","article-title":"Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case- control study","volume":"67","author":"Yamamoto","year":"2006","journal-title":"Neurology."},{"key":"10.4158\/EP.14.6.672_bb0020","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/mds.20201","article-title":"Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists","volume":"19","author":"Horvath","year":"2004","journal-title":"Mov Disord."},{"key":"10.4158\/EP.14.6.672_bb0025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/mds.21225","article-title":"Valvular heart disease in Parkinson\u2019s disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study","volume":"22","author":"Junghanns","year":"2007","journal-title":"Mov Disord."},{"key":"10.4158\/EP.14.6.672_bb0030","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clineuro.2007.01.011","article-title":"Assessment of valvulopathy in Parkinson\u2019s disease patients on pergolide and\/or cabergoline","volume":"109","author":"Kenangil","year":"2007","journal-title":"Clin Neurol Neurosurg."},{"key":"10.4158\/EP.14.6.672_bb0035","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.ijcard.2006.07.020","article-title":"Mitral heart disease due to cabergoline","volume":"114","author":"Martin","year":"2007","journal-title":"Int J Cardiol."},{"key":"10.4158\/EP.14.6.672_bb0040","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/mds.20887","article-title":"Valvular heart disease in Parkinson\u2019s disease vs. controls: an echocardiographic study","volume":"21","author":"Peralta","year":"2006","journal-title":"Mov Disord."},{"key":"10.4158\/EP.14.6.672_bb0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp068265","article-title":"Drugs and valvular heart disease","volume":"356","author":"Roth","year":"2007","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.14.6.672_bb0050","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/ncpneuro0534","article-title":"Dopamine agonists and the risk of valvular heart disease","volume":"3","author":"Martin","year":"2007","journal-title":"Nat Clin Pract Neurol."},{"key":"10.4158\/EP.14.6.672_bb0055","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.clinthera.2006.08.004","article-title":"A review of the receptor-binding and pharmacokinetic properties of dopamine agonists","volume":"28","author":"Kvernmo","year":"2006","journal-title":"Clin Ther."},{"key":"10.4158\/EP.14.6.672_bb0060","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0894-7317(03)00335-3","article-title":"(American Society of Echocardiography). Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography","volume":"16","author":"Zoghbi","year":"2003","journal-title":"J Am Soc Echocardiogr."},{"key":"10.4158\/EP.14.6.672_bb0065","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.amjcard.2006.10.048","article-title":"Prevalence and clinical correlates of isolated mitral, isolated aortic regurgitation, and both in adults aged 21 to 35 years (from the CARDIA study)","volume":"99","author":"Reid","year":"2007","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP.14.6.672_bb0070","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0002-9149(98)01064-9","article-title":"Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study) [published correction appears in Am J Cardiol. 1999;84:1143]","volume":"83","author":"Singh","year":"1999","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP.14.6.672_bb0075","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/01.CIR.101.17.2071","article-title":"Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities","volume":"101","author":"Jollis","year":"2000","journal-title":"Circulation."},{"key":"10.4158\/EP.14.6.672_bb0080","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199809103391103","article-title":"(Sustained-Release Dexfenfluramine Study Group). An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo","volume":"339","author":"Weissman","year":"1998","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.14.6.672_bb0085","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1056\/NEJMc053329","article-title":"Cabergoline and mitral regurgitation","volume":"354","author":"Delgrange","year":"2006","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.14.6.672_bb0090","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1001\/jama.283.13.1703","article-title":"Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine\/fenfluramine","volume":"283","author":"Gardin","year":"2000","journal-title":"JAMA."},{"key":"10.4158\/EP.14.6.672_bb0095","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0735-1097(99)00321-6","article-title":"Low prevalence of valvular heart disease in 226 phenterminefen-fluramine protocol subjects prospectively followed for up to 30 months","volume":"34","author":"Burger","year":"1999","journal-title":"J Am Coll Cardiol."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20412789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20412789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/R1T5713015251K44.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:48:20Z","timestamp":1761515300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20412789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S1530891X20412789"],"URL":"https:\/\/doi.org\/10.4158\/ep.14.6.672","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of Valvular Heart Disease in A Cohort of Patients Taking Cabergoline for Management of Hyperprolactinemia","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP.14.6.672","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}